Skip to main content
Top
Published in: BMC Medical Genetics 1/2004

Open Access 01-12-2004 | Research article

Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes

Authors: Connie E Byrne, Anthony Fitzgerald, Christopher P Cannon, Desmond J Fitzgerald, Denis C Shields

Published in: BMC Medical Genetics | Issue 1/2004

Login to get access

Abstract

Background

Elevated white blood cell counts (WBC) in acute coronary syndromes (ACS) increase the risk of recurrent events, but it is not known if this is exacerbated by pro-inflammatory factors. We sought to identify whether pro-inflammatory genetic variants contributed to alterations in WBC and C-reactive protein (CRP) in an ACS population.

Methods

WBC and genotype of interleukin 6 (IL-6 G-174C) and of interleukin-1 receptor antagonist (IL1RN intronic repeat polymorphism) were investigated in 732 Caucasian patients with ACS in the OPUS-TIMI-16 trial. Samples for measurement of WBC and inflammatory factors were taken at baseline, i.e. Within 72 hours of an acute myocardial infarction or an unstable angina event.

Results

An increased white blood cell count (WBC) was associated with an increased C-reactive protein (r = 0.23, p < 0.001) and there was also a positive correlation between levels of β-fibrinogen and C-reactive protein (r = 0.42, p < 0.0001). IL1RN and IL6 genotypes had no significant impact upon WBC. The difference in median WBC between the two homozygote IL6 genotypes was 0.21/mm3 (95% CI = -0.41, 0.77), and -0.03/mm3 (95% CI = -0.55, 0.86) for IL1RN. Moreover, the composite endpoint was not significantly affected by an interaction between WBC and the IL1 (p = 0.61) or IL6 (p = 0.48) genotype.

Conclusions

Cytokine pro-inflammatory genetic variants do not influence the increased inflammatory profile of ACS patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis. 2000, 148: 209-214. 10.1016/S0021-9150(99)00463-3.CrossRefPubMed Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis. 2000, 148: 209-214. 10.1016/S0021-9150(99)00463-3.CrossRefPubMed
2.
go back to reference Lowe GD, Machado SG, Krol WF, Barton BA, Forbes CD: White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction. Thromb Haemost. 1985, 54: 700-703.PubMed Lowe GD, Machado SG, Krol WF, Barton BA, Forbes CD: White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction. Thromb Haemost. 1985, 54: 700-703.PubMed
3.
go back to reference Burr ML, Holliday RM, Fehily AM, Whitehead PJ: Haematological prognostic indices after myocardial infarction: evidence from the diet and reinfarction trial (DART). Eur Heart J. 1992, 13: 166-170.PubMed Burr ML, Holliday RM, Fehily AM, Whitehead PJ: Haematological prognostic indices after myocardial infarction: evidence from the diet and reinfarction trial (DART). Eur Heart J. 1992, 13: 166-170.PubMed
4.
go back to reference Cannon CP, McCabe CH, Wilcox RG, Bentley JH, Braunwald E: Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol. 2001, 87: 636-9, A10. 10.1016/S0002-9149(00)01444-2.CrossRefPubMed Cannon CP, McCabe CH, Wilcox RG, Bentley JH, Braunwald E: Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol. 2001, 87: 636-9, A10. 10.1016/S0002-9149(00)01444-2.CrossRefPubMed
5.
go back to reference Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM: Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation. 2000, 102: 2329-2334.CrossRefPubMed Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM: Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation. 2000, 102: 2329-2334.CrossRefPubMed
6.
go back to reference Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, Harris TB: Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study. Circulation. 2001, 103: 947-953.CrossRefPubMed Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, Harris TB: Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study. Circulation. 2001, 103: 947-953.CrossRefPubMed
7.
go back to reference Rosalki SB: C-reactive protein. Int J Clin Pract. 2001, 55: 269-270.PubMed Rosalki SB: C-reactive protein. Int J Clin Pract. 2001, 55: 269-270.PubMed
8.
go back to reference Berk BC, Weintraub WS, Alexander RW: Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol. 1990, 65: 168-172. 10.1016/0002-9149(90)90079-G.CrossRefPubMed Berk BC, Weintraub WS, Alexander RW: Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol. 1990, 65: 168-172. 10.1016/0002-9149(90)90079-G.CrossRefPubMed
9.
go back to reference Liuzzo G, Biasucci LM, Rebuzzi AG, Gallimore JR, Caligiuri G, Lanza GA, Quaranta G, Monaco C, Pepys MB, Maseri A: Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation. 1996, 94: 2373-2380.CrossRefPubMed Liuzzo G, Biasucci LM, Rebuzzi AG, Gallimore JR, Caligiuri G, Lanza GA, Quaranta G, Monaco C, Pepys MB, Maseri A: Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation. 1996, 94: 2373-2380.CrossRefPubMed
10.
go back to reference Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A: The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994, 331: 417-424. 10.1056/NEJM199408183310701.CrossRefPubMed Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A: The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994, 331: 417-424. 10.1056/NEJM199408183310701.CrossRefPubMed
11.
go back to reference Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB: Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997, 349: 462-466. 10.1016/S0140-6736(96)07591-5.CrossRefPubMed Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB: Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997, 349: 462-466. 10.1016/S0140-6736(96)07591-5.CrossRefPubMed
12.
go back to reference Zebrack JS, Anderson JL, Maycock CA, Horne BD, Bair TL, Muhlestein JB: Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol. 2002, 89: 145-149. 10.1016/S0002-9149(01)02190-7.CrossRefPubMed Zebrack JS, Anderson JL, Maycock CA, Horne BD, Bair TL, Muhlestein JB: Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol. 2002, 89: 145-149. 10.1016/S0002-9149(01)02190-7.CrossRefPubMed
13.
go back to reference Toss H, Gnarpe J, Gnarpe H, Siegbahn A, Lindahl B, Wallentin L: Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. Eur Heart J. 1998, 19: 570-577. 10.1053/euhj.1997.0771.CrossRefPubMed Toss H, Gnarpe J, Gnarpe H, Siegbahn A, Lindahl B, Wallentin L: Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. Eur Heart J. 1998, 19: 570-577. 10.1053/euhj.1997.0771.CrossRefPubMed
14.
go back to reference Levenson J, Giral P, Razavian M, Gariepy J, Simon A: Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 1995, 15: 1263-1268.CrossRefPubMed Levenson J, Giral P, Razavian M, Gariepy J, Simon A: Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 1995, 15: 1263-1268.CrossRefPubMed
15.
go back to reference Tracy RP, Bovill EG, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ: Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1995, 15: 1269-1279.CrossRefPubMed Tracy RP, Bovill EG, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ: Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1995, 15: 1269-1279.CrossRefPubMed
16.
go back to reference Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D: Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood. 1999, 93: 4277-4283.PubMed Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D: Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood. 1999, 93: 4277-4283.PubMed
17.
go back to reference Yarnell JW, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC: Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation. 1991, 83: 836-844.CrossRefPubMed Yarnell JW, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC: Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation. 1991, 83: 836-844.CrossRefPubMed
18.
go back to reference Panichi V, Migliori M, De Pietro S, Taccola D, Andreini B, Metelli MR, Giovannini L, Palla R: The link of biocompatibility to cytokine production. Kidney Int Suppl. 2000, 76: S96-103. 10.1046/j.1523-1755.2000.07612.x.CrossRefPubMed Panichi V, Migliori M, De Pietro S, Taccola D, Andreini B, Metelli MR, Giovannini L, Palla R: The link of biocompatibility to cytokine production. Kidney Int Suppl. 2000, 76: S96-103. 10.1046/j.1523-1755.2000.07612.x.CrossRefPubMed
19.
go back to reference Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U: Fibrinogen is a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group. Arterioscler Thromb Vasc Biol. 1996, 16: 351-356.CrossRefPubMed Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U: Fibrinogen is a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group. Arterioscler Thromb Vasc Biol. 1996, 16: 351-356.CrossRefPubMed
20.
go back to reference Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R: Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1999, 19: 2364-2367.CrossRefPubMed Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R: Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1999, 19: 2364-2367.CrossRefPubMed
21.
go back to reference El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni J. F., Jr., Rabkin CS: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000, 404: 398-402. 10.1038/35006081.CrossRefPubMed El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni J. F., Jr., Rabkin CS: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000, 404: 398-402. 10.1038/35006081.CrossRefPubMed
22.
go back to reference Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, Duff GW: Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet. 1993, 91: 403-404.CrossRefPubMed Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, Duff GW: Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet. 1993, 91: 403-404.CrossRefPubMed
23.
go back to reference Cork MJ, Tarlow JK, Clay FE, Crane A, Blakemore AI, McDonagh AJ, Messenger AG, Duff GW: An allele of the interleukin-1 receptor antagonist as a genetic severity factor in alopecia areata. J Invest Dermatol. 1995, 104: 15S-16S.CrossRefPubMed Cork MJ, Tarlow JK, Clay FE, Crane A, Blakemore AI, McDonagh AJ, Messenger AG, Duff GW: An allele of the interleukin-1 receptor antagonist as a genetic severity factor in alopecia areata. J Invest Dermatol. 1995, 104: 15S-16S.CrossRefPubMed
24.
go back to reference Blakemore AI, Cox A, Gonzalez AM, Maskil JK, Hughes ME, Wilson RM, Ward JD, Duff GW: Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum Genet. 1996, 97: 369-374. 10.1007/s004390050055.CrossRefPubMed Blakemore AI, Cox A, Gonzalez AM, Maskil JK, Hughes ME, Wilson RM, Ward JD, Duff GW: Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum Genet. 1996, 97: 369-374. 10.1007/s004390050055.CrossRefPubMed
25.
go back to reference Witkin SS, Gerber S, Ledger WJ: Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis. 2002, 34: 204-209. 10.1086/338261.CrossRefPubMed Witkin SS, Gerber S, Ledger WJ: Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis. 2002, 34: 204-209. 10.1086/338261.CrossRefPubMed
26.
go back to reference Shibata M, Endo S, Inada K, Kuriki S, Harada M, Takino T, Sato N, Arakawa N, Suzuki T, Aoki H, Hiramori K: Elevated plasma levels of interleukin-1 receptor antagonist and interleukin-10 in patients with acute myocardial infarction. J Interferon Cytokine Res. 1997, 17: 145-150.CrossRefPubMed Shibata M, Endo S, Inada K, Kuriki S, Harada M, Takino T, Sato N, Arakawa N, Suzuki T, Aoki H, Hiramori K: Elevated plasma levels of interleukin-1 receptor antagonist and interleukin-10 in patients with acute myocardial infarction. J Interferon Cytokine Res. 1997, 17: 145-150.CrossRefPubMed
27.
go back to reference Francis SE, Camp NJ, Dewberry RM, Gunn J, Syrris P, Carter ND, Jeffery S, Kaski JC, Cumberland DC, Duff GW, Crossman DC: Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation. 1999, 99: 861-866.CrossRefPubMed Francis SE, Camp NJ, Dewberry RM, Gunn J, Syrris P, Carter ND, Jeffery S, Kaski JC, Cumberland DC, Duff GW, Crossman DC: Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation. 1999, 99: 861-866.CrossRefPubMed
28.
go back to reference Zee RY, Lunze K, Lindpaintner K, Ridker PM: A prospective evaluation of the interleukin-1 receptor antagonist intron 2 gene polymorphism and the risk of myocardial infarction. Thromb Haemost. 2001, 86: 1141-1143.PubMed Zee RY, Lunze K, Lindpaintner K, Ridker PM: A prospective evaluation of the interleukin-1 receptor antagonist intron 2 gene polymorphism and the risk of myocardial infarction. Thromb Haemost. 2001, 86: 1141-1143.PubMed
29.
go back to reference Burzotta F, Iacoviello L, Di Castelnuovo A, Glieca F, Luciani N, Zamparelli R, Schiavello R, Donati MB, Maseri A, Possati G, Andreotti F: Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol. 2001, 88: 1125-1128. 10.1016/S0002-9149(01)02046-X.CrossRefPubMed Burzotta F, Iacoviello L, Di Castelnuovo A, Glieca F, Luciani N, Zamparelli R, Schiavello R, Donati MB, Maseri A, Possati G, Andreotti F: Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol. 2001, 88: 1125-1128. 10.1016/S0002-9149(01)02046-X.CrossRefPubMed
30.
go back to reference Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998, 102: 1369-1376.CrossRefPubMedPubMedCentral Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998, 102: 1369-1376.CrossRefPubMedPubMedCentral
31.
go back to reference Foster CB, Lehrnbecher T, Samuels S, Stein S, Mol F, Metcalf JA, Wyvill K, Steinberg SM, Kovacs J, Blauvelt A, Yarchoan R, Chanock SJ: An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood. 2000, 96: 2562-2567.PubMed Foster CB, Lehrnbecher T, Samuels S, Stein S, Mol F, Metcalf JA, Wyvill K, Steinberg SM, Kovacs J, Blauvelt A, Yarchoan R, Chanock SJ: An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood. 2000, 96: 2562-2567.PubMed
32.
go back to reference Rauramaa R, Vaisanen SB, Luong LA, Schmidt-Trucksass A, Penttila IM, Bouchard C, Toyry J, Humphries SE: Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol. 2000, 20: 2657-2662.CrossRefPubMed Rauramaa R, Vaisanen SB, Luong LA, Schmidt-Trucksass A, Penttila IM, Bouchard C, Toyry J, Humphries SE: Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol. 2000, 20: 2657-2662.CrossRefPubMed
33.
go back to reference Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, Lopez-Sendon J, Toman J, Charlesworth A, Anders RJ, Alexander JC, Skene A, Braunwald E: Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000, 102: 149-156.CrossRefPubMed Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, Lopez-Sendon J, Toman J, Charlesworth A, Anders RJ, Alexander JC, Skene A, Braunwald E: Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000, 102: 149-156.CrossRefPubMed
34.
go back to reference O'Neill WW, Serruys P, Knudtson M, van Es GA, Timmis GC, van der Zwaan C, Kleiman J, Gong J, Roecker EB, Dreiling R, Alexander J, Anders R: Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med. 2000, 342: 1316-1324. 10.1056/NEJM200005043421803.CrossRefPubMed O'Neill WW, Serruys P, Knudtson M, van Es GA, Timmis GC, van der Zwaan C, Kleiman J, Gong J, Roecker EB, Dreiling R, Alexander J, Anders R: Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med. 2000, 342: 1316-1324. 10.1056/NEJM200005043421803.CrossRefPubMed
35.
go back to reference Shields DC, Fitzgerald AP, O'Neill PA, Muckian C, Kenny D, Moran B, Cannon CP, Byrne CE, Fitzgerald DJ: The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists. Pharmacogenomics J. 2002, 2: 182-190. 10.1038/sj.tpj.6500100.CrossRefPubMed Shields DC, Fitzgerald AP, O'Neill PA, Muckian C, Kenny D, Moran B, Cannon CP, Byrne CE, Fitzgerald DJ: The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists. Pharmacogenomics J. 2002, 2: 182-190. 10.1038/sj.tpj.6500100.CrossRefPubMed
36.
go back to reference Zee RY, Ridker PM: Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis. 2002, 162: 217-219. 10.1016/S0021-9150(01)00703-1.CrossRefPubMed Zee RY, Ridker PM: Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis. 2002, 162: 217-219. 10.1016/S0021-9150(01)00703-1.CrossRefPubMed
37.
go back to reference Fernandez-Real JM, Vendrell J, Richart C, Gutierrez C, Ricart W: Platelet count and Interleukin 6 Gene polymorphism in healthy subjects. BMC Med Genet. 2001, 2: 6-9. 10.1186/1471-2350-2-6.CrossRefPubMedPubMedCentral Fernandez-Real JM, Vendrell J, Richart C, Gutierrez C, Ricart W: Platelet count and Interleukin 6 Gene polymorphism in healthy subjects. BMC Med Genet. 2001, 2: 6-9. 10.1186/1471-2350-2-6.CrossRefPubMedPubMedCentral
38.
go back to reference Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, Weyrich AS: Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol. 2001, 154: 485-490. 10.1083/jcb.200105058.CrossRefPubMedPubMedCentral Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, Weyrich AS: Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol. 2001, 154: 485-490. 10.1083/jcb.200105058.CrossRefPubMedPubMedCentral
Metadata
Title
Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes
Authors
Connie E Byrne
Anthony Fitzgerald
Christopher P Cannon
Desmond J Fitzgerald
Denis C Shields
Publication date
01-12-2004
Publisher
BioMed Central
Published in
BMC Medical Genetics / Issue 1/2004
Electronic ISSN: 1471-2350
DOI
https://doi.org/10.1186/1471-2350-5-13

Other articles of this Issue 1/2004

BMC Medical Genetics 1/2004 Go to the issue